HOME >> BIOLOGY >> NEWS
Other highlights in the May 19 JNCI

Two Studies Examine Safe Three Agent Combination Therapy for HER2-Positive Advanced Breast Cancer

Combinations of docetaxel, cisplatin or carboplatin, and the monoclonal antibody trastuzumab are feasible for the treatment of patients with HER2-positive advanced breast cancer in which tumor response rates are high, according to two new studies.

Human epidermal growth factor receptor 2 (HER2) is overexpressed in the tumors of 20-30% of breast cancer patients and is associated with an increased risk of relapse and death in patients with early-stage breast cancer. In earlier clinical trials, adding trastuzumab, which blocks the effects of HER2, to standard chemotherapy increased both the response rate of patients and survival, but an unacceptable number of patients experienced cardiac dysfunction, including congestive heart disease.

In the first of two studies designed to find safer chemotherapy combinations that include trastuzumab, Mark D. Pegram, M.D., of the University of California, Los Angeles, and colleagues characterized the interactions between trastuzumab and nine chemotherapy drugs commonly used in treating breast cancer in four cell lines that overexpress HER2. They found synergistic interactions of trastuzumab plus carboplatin, 4-hydroxycyclophosphamide, docetaxel, or vinorelbine, which indicated that these were reasonable combinations to test in human clinical trials.

In the second study, a second group of researchers also led by Pegram, conducted two phase II clinical trials to evaluate the combination of docetaxel and trastuzumab with either of two platinum salts, cisplatin or carboplatin. In each trial, the combinations were tested on 62 women with advanced breast cancer that overexpressed HER2. Both combinations had a similar toxicity to docetaxel plus platinum salts alone, and there was a low incidence of cardiac dysfunction. In addition, overall response rates were higher. The combinations are now being tested
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
18-May-2004


Page: 1 2 3 4

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the July 7 JNCI
5. Other highlights in the June 16 JNCI
6. Other Highlights in the June 2 JNCI
7. Other highlights in the May 5 JNCI
8. Other highlights of the March 17 issue of JNCI
9. Other highlights in the March 3 issue of JNCI
10. Other highlights in the February 18 issue of JNCI
11. Other highlights in the February 4 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/24/2020)... ... ... Shoreline Biome , a microbiome research company that develops tools for characterizing ... a novel new DNA isolation kit at the Miami Winter Symposium 2020 , ... is a fast and easy-to-use kit designed for the efficient and unbiased isolation of ...
(Date:1/24/2020)... , ... January 24, 2020 , ... Worldwide Business ... President Dr. Stanley Stanbridge and Vice President of Sales and Marketing Jeff Maier ... Business Network as sponsored content on Sunday, Jan. 26, 2020 at 5:30 p.m. EST ...
(Date:1/23/2020)... ... January 23, 2020 , ... GIOSTAR/HEAMGEN has developed ... cells. The red blood cells are made utilizing a bioreactor that permits ... therapy and replaces the need for a human blood donor. GIOSTAR/HEAMGEN ...
Breaking Biology News(10 mins):
(Date:2/5/2020)... ... February 05, 2020 , ... Rare Disease Day® , ... The National Organization for Rare Disorders (NORD), to raise awareness amongst the general public ... The Balancing Act’s “Behind The Mystery” rare disease series will be ...
(Date:1/28/2020)... ... January 28, 2020 , ... Lifecycle Biotechnologies ... and beverage manufactures within North America. Both Lifecycle and Midland have supported this ... each company to pool their collective resources and provide the industry with support, ...
(Date:1/27/2020)... , ... January 27, 2020 , ... ... in neuroscience and cloud and mobile computing, today announced the availability of neuroscience ... an organization to use the latest neuroscience of leadership and change research to ...
(Date:1/24/2020)... (PRWEB) , ... January 24, 2020 , ... ... innovations created by companies in biotechnology, diagnostics, therapeutics, laboratory and clinical services during ... millions of people around the world. And as Slone Partners celebrates ...
Breaking Biology Technology:
Cached News: